8-K: Precision BioSciences Advances Gene Editing Programs, Reports Q3 2024 Financials

Precision BioSciences announced its third quarter 2024 financial results and provided a business update, highlighting the advancement of its gene editing programs, including the first clinical trial application approval for PBGENE-HBV.

Summary

• Precision BioSciences reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company received approval for its first Clinical Trial Application (CTA) for PBGENE-HBV, a treatment for chronic hepatitis B, and has initiated patient screening in Moldova.
• Precision expects to report Phase 1 PBGENE-HBV data throughout 2025 and plans to submit an IND or CTA for PBGENE-3243, a treatment for mitochondrial disease, in 2025.
• The company's cash runway is expected to extend into the second half of 2026, sufficient to fund multiple in vivo gene editing programs through Phase 1 data readouts.
• Total revenue for the quarter was $0.6 million, a decrease from $13.1 million in the same period of 2023, primarily due to reduced revenue from the Novartis and Prevail agreements.
• Research and development expenses decreased to $13.1 million from $15.9 million in the same quarter of the previous year, while net loss increased to $16.4 million from $12.1 million.
• As of September 30, 2024, Precision had approximately $121.3 million in cash, cash equivalents, and restricted cash.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and technology, the financial results show a significant decrease in revenue and an increase in net loss. The company's cash runway is positive, but the overall sentiment is neutral to slightly negative due to the financial performance.

Positives

• The approval of the first CTA for PBGENE-HBV marks a significant milestone for the company.
• The initiation of patient screening in Moldova is a positive step forward for the PBGENE-HBV program.
• The company's cash runway extending into the second half of 2026 provides financial stability.
• The advancement of PBGENE-3243 towards an IND or CTA submission in 2025 demonstrates progress in the pipeline.
• The company has strengthened its senior leadership team with key clinical talent.

Negatives

• The significant decrease in revenue compared to the same period last year is a concern.
• The increase in net loss for the quarter is a negative indicator.
• The company is still in the early stages of clinical development, which carries inherent risks.

Risks

• The company's ability to successfully complete clinical trials and obtain regulatory approvals is uncertain.
• There are risks associated with the development and commercialization of gene editing therapies.
• The company faces competition in the gene editing, biopharmaceutical, and biotechnology fields.
• The company's financial performance is dependent on its ability to secure funding and generate revenue.
• There are risks associated with the company's reliance on its ARCUS technology.

Future Outlook

The company expects to report Phase 1 PBGENE-HBV data throughout 2025 and plans to submit an IND or CTA for PBGENE-3243 in 2025. The company's cash runway is expected to extend into the second half of 2026, sufficient to fund multiple in vivo gene editing programs through Phase 1 data readouts.

Management Comments

• Michael Amoroso, Chief Executive Officer, stated that the company has arrived at the next phase of its journey as a single platform, clinical stage in vivo gene editing company.
• Mr. Amoroso also mentioned that the team is moving quickly to dose patients and is leveraging its regulatory package to seek additional approvals globally.

Industry Context

This announcement highlights the growing interest and activity in the gene editing space, particularly in the development of in vivo therapies for genetic and infectious diseases. The company's focus on its proprietary ARCUS platform and its differentiated approach to gene editing positions it as a potential player in the field.

Comparison to Industry Standards

• Precision BioSciences' approach to gene editing using ARCUS is differentiated from CRISPR/Cas, base editors, and prime editors, which require a guide RNA.
• The company's focus on in vivo gene editing is aligned with the industry trend towards more direct and efficient therapeutic delivery.
• The company's PBGENE-HBV program is the first potentially curative gene editing program to enter clinic specifically designed to eliminate cccDNA and inactivate integrated HBV DNA, which is a unique approach compared to other hepatitis B treatments.
• The company's reported 40% to 45% high efficiency gene insertion in non-dividing cells in non-human primates is a strong result compared to other gene editing technologies.
• The company's reported 85% gene insertion in T cells is also a strong result compared to other gene editing technologies.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and increase in net loss.
• Employees may be encouraged by the progress in clinical trials and the company's financial stability.
• Patients with chronic hepatitis B and mitochondrial diseases may benefit from the company's gene editing therapies.
• Partners and collaborators may be interested in the company's progress and future plans.

Next Steps

• The company will continue patient screening for the PBGENE-HBV Phase 1 clinical program in Moldova.
• Precision will seek additional regulatory application approvals globally for PBGENE-HBV.
• The company will submit an IND or CTA for PBGENE-3243 in 2025.
• Precision will host a virtual investor event on November 15, 2024, to discuss PBGENE-HBV.
• The company will continue to advance its partnered programs with iECURE and Novartis.

Key Dates

Keywords

gene editing, ARCUS, PBGENE-HBV, PBGENE-3243, clinical trial, hepatitis B, mitochondrial disease, in vivo, biotechnology, financial results